ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer

ClinicalTrials.gov ID: NCT00312377

Public ClinicalTrials.gov record NCT00312377. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 7:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Double-Blinded, Multi-Center, Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination With ZD6474 (ZACTIMA™) Versus Docetaxel (TAXOTERE™) With Placebo in Subjects With Locally Advanced or Metastatic NSCLC

Study identification

NCT ID
NCT00312377
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Genzyme, a Sanofi Company
Industry
Enrollment
1,690 participants

Conditions and interventions

Interventions

  • Docetaxel Drug
  • Vandetanib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2006
Primary completion
Jul 31, 2008
Completion
Feb 28, 2014
Last update posted
Sep 29, 2016

2006 – 2014

United States locations

U.S. sites
27
U.S. states
19
U.S. cities
27
Facility City State ZIP Site status
Research Site Fullerton California
Research Site Los Angeles California
Research Site Northridge California
Research Site Colorado Springs Colorado
Research Site Norwalk Connecticut
Research Site Ocala Florida
Research Site Marietta Georgia
Research Site Joliet Illinois
Research Site Park Ridge Illinois
Research Site Hutchinson Kansas
Research Site Louisville Kentucky
Research Site Boston Massachusetts
Research Site Ann Arbor Michigan
Research Site St Louis Missouri
Research Site Henderson Nevada
Research Site Albany New York
Research Site Armonk New York
Research Site New York New York
Research Site Durham North Carolina
Research Site Hickory North Carolina
Research Site Portland Oregon
Research Site Austin Texas
Research Site Houston Texas
Research Site Ogden Utah
Research Site Alexandria Virginia
Research Site Salem Virginia
Research Site Vancouver Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 129 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00312377, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 29, 2016 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00312377 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →